How to Buy Cg Oncology Stock
Cg Oncology Inc
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer.
Cg Oncology stock last closed at $26.94, down 3.68% from the previous day, and has decreased 37.81% in one year. It has overperformed other stocks in the Biotechnology industry by 0.4 percentage points. Cg Oncology stock is currently +82.03% from its 52-week low of $14.80, and -42.67% from its 52-week high of $46.99.
As of Apr 29, 2025, there are 76.22M shares of CGON outstanding. The market capitalization of CGON is $2.05B. In the past 24 hours, 1.97M CGON shares were traded.
How to Buy Cg Oncology Stock
Wondering how to invest in Cg Oncology stock? Here's how.
- Decide where to buy Cg Oncology stock: You need to decide on an online brokerage, but don't worry - we've sifted through dozens of stock brokerages and apps to help you determine where to buy Cg Oncology stock.
- Sign up for your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've identified.
- Fund your brokerage account: Pick your method of payment and add your details.
- Analyze Cg Oncology stock: The Cg Oncology ticker symbol is CGON. Is Cg Oncology stock a good investment? Should you buy shares of CGON? How do CGON's underlying business fundamentals look? Do top analysts think Cg Oncology is a good buy? Why has CGON's stock price moved recently? (Hint: Our stock research website can help you evaluate if CGON is a good stock to buy).
- Place your CGON trade: Decide if you will purchase CGON shares at the current market price or use a limit order to purchase CGON shares at a specific price.
- Get updates on your investment in CGON: Create a watchlist to the latest updates on your investment in Cg Oncology stock.
Step 1: Decide where to buy Cg Oncology stock
You will need an online brokerage account in order to access the NASDAQ market and buy CGON shares.
Our preferred brokerage: eToro
Based on our analysis, eToro is the best place to buy stocks. Here's why:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you can't afford a full share, you can still invest in the stock.
- Access to global markets: From Tech to Real Estate, New York to Tokyo (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's leading exchanges.
- Social investing: eToro offers a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro now. This offer is only for US users.
Open eToro AccountStep 2: Sign up for your brokerage account
Now that you've chosen the right brokerage, the next step is to fill out some personal information so you can invest in CGON stock today.
How to Set Up a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Provide your personal data to create a new brokerage account.
- Submit your details by clicking the "Create Account" button. Get started with eToro today
Step 3: Fund your brokerage account
Now that you have filled out your info on the highest rated app to buy and sell stocks, your next step is to transfer the money for your investment:
Check out the tutorial below for more details depositing funds into your brokerage account.
Step 4: Analyze Cg Oncology stock
Once you have identified the best place to buy Cg Oncology stock, it's absolutely critical to evaluate their stock prior to buying, so you truly wrap your head around the risk and upside.
Cg Oncology stock at a glance
Cg Oncology Due Diligence Checks
WallStreetZen was created to help part-time investors do more accurate fundamental analysis.
You can see all of the due diligence checks on CGON's stock page.
Is CGON stock undervalued or overvalued?
Analysts use many financial metrics, analyses, models, and charts to gauge CGON's intrinsic value.
Using relative valuations metrics:
- CGON may be undervalued based on its P/B ratio of 2.8x, relative to Biotechnology industry P/B ratio of 4.37x
You can access additional valuation analysis on CGON's stock here.
A quick look at CGON Financials
Passed Financial Due Diligence Checks:
- CGON has $742.00M in cash and short term investments. This is enough to cover its annual cash burn of $78.95M.
- CGON has cash burn of 78947000. It has enough cash and short-term investments to cover this for at least one year.
- CGON has a low debt to equity ratio of 0.03.
- There are more short-term assets than long-term liabilities on the CGON balance sheet.
- There are more short-term assets than short-term liabilities on the CGON balance sheet.
Failed Financial Due Diligence Checks:
- CGON profit margin has gone up by 255.05 percentage points in the past year, but the company is still unprofitable.
Is it a good time to buy CGON stock, according to Wall Street analysts?
Out of 5 Equities analysts who give ratings on CGON, the consensus analyst rating on Cg Oncology is a Strong Buy
Please note that analyst forecasts are not stock recommendations, nor are they investment advice.
Most Recent CGON Analyst Upgrades/Downgrades
Andrew Fein, a bottom 9% analyst from HC Wainwright & Co. reiterates CGON with a buy rating and maintains their CGON price target from $75.00 to $75.00, on Jan 13, 2025.
You can dive deeper into what analysts are projecting on the Cg Oncology stock forecast page.
CGON Trading Indicators
CGON Performance Metrics
Last year, CGON revenue was $1.14M. During the past 3 year, CGON's revenue has grown by -96.19% per year. This was slower than the Biotechnology industry average of 45.47%.
Learn more about CGON's earnings and revenue performance here.
Who is buying/selling CGON?
In the last 12 months, executives and large shareholders at CGON have sold more shares than they have bought.
Leonard E. Post, Director of CGON, was the latest CGON insider to buy. They bought $600.00 worth of CGON stock on Apr 28, 2025.
Dig into more about who owns CGON shares here.
Can I get consistent income from CGON stock?
No, Cg Oncology doesn't provide an income stream by paying out dividends.
CGON Social Trading Data
One of the reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Place your CGON trade
There are two main options:
- Market order: A market order is an order to buy or sell a security at the best possible price.
Market orders are generally fine for most investors. - Limit order: A limit order allows you to buy or sell a stock at a specific price (or better).
If you want to be sure you're buying or selling at a particular dollar amount, use a limit order.
Click the Open button and your broker will execute your order.
If you want more assistance buying stocks on eToro, click the how to video below:
Step 6: Get updates on your investment in CGON
Now that you own some CGON shares, you'll want to keep up with your new investment.
Start a watchlist to get the latest updates about your CGON stock.
CGON Feed
How to Buy Stock in Cg Oncology
To reiterate, here are the 6 steps to buy stock in Cg Oncology:
- Decide where to buy Cg Oncology stock
- Sign up for your brokerage account
- Fund your brokerage account
- Analyze Cg Oncology stock
- Place your CGON trade
- Get updates on your investment in CGON
If you require a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you want to track your investment in Cg Oncology, create a watchlist today.
Other "How To" Guides You May Like
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.